Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, single-blind, investigator-initiated pharmacological
study with a crossover design. Patients with acute coronary syndrome (ST-elevation myocardial
infarction, non-ST elevation myocardial infarction, unstable angina) and presenting high
on-clopidogrel platelet reactivity as assessed with the VerifyNow assay (platelet reactivity
units PRU≥235) 24 hours post percutaneous coronary intervention (PCI), will be randomized
after informed consent in a 1:1 ratio to either prasugrel 10mg/d or ticagrelor 90mg twice a
day for 15 days. Platelet reactivity assessment will be performed at Day 15±2 days and then a
crossover directly to the alternate treatment group for an additional 15 days period, without
an intervening washout period will be carried out. Patients will return at Day 30±2 days for
platelet reactivity assessment.